Aytu BioPharma, Inc.

NasdaqCM:AYTU Lagerbericht

Marktkapitalisierung: US$23.1m

Aytu BioPharma Management

Management Kriterienprüfungen 3/4

Aytu BioPharma CEO ist Josh Disbrow , ernannt in Apr 2015, hat eine Amtszeit von 11.17 Jahren. Die jährliche Gesamtvergütung beträgt $883.93K , bestehend aus 66.7% Gehalt und 33.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.93% der Aktien des Unternehmens, im Wert von $445.49K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.6 Jahre bzw. 9.9 Jahre.

Wichtige Informationen

Josh Disbrow

Geschäftsführender

US$883.9k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts66.75%
Amtszeit als Geschäftsführer11.2yrs
Eigentum des Geschäftsführers1.9%
Durchschnittliche Amtszeit des Managements3.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder9.9yrs

Jüngste Management Updates

Analyseartikel • May 14

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation

Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...
Analyseartikel • Jun 20

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...

Recent updates

Analyseartikel • Dec 20

Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have had a really impressive month, gaining 28% after a shaky period...
Analyseartikel • Nov 17

Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...
Analyseartikel • Oct 30

There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price Rise

Those holding Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares would be relieved that the share price has rebounded 27% in...
Analyseartikel • Jul 29

Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks Justified

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have continued their recent momentum with a 25% gain in the last month...
Analyseartikel • May 14

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation

Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...
Analyseartikel • May 04

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 27% in...
Analyseartikel • Jan 18

Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 28% in...
Analyseartikel • Nov 15

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%

To the annoyance of some shareholders, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares are down a considerable 32% in the...
Analyseartikel • Nov 01

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyseartikel • Jun 20

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...
Analyseartikel • Jun 14

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analyseartikel • Feb 17

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its latest quarterly results and things are looking bullish. Results...
Analyseartikel • Feb 16

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Despite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...
Analyseartikel • Jan 23

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Sep 29

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders have had their patience rewarded with a 59% share price jump in the...
Seeking Alpha • Oct 13

Aytu stock falls amid suspending clinical programs to save costs

Aytu BioPharma (NASDAQ:AYTU) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlos Syndrome (VEDS), Healight, and NT0502. Aytu is expecting to generate positive quarterly adjusted EBITDA in H1 calendar year 2023. "This strategic realignment enables us to dedicate our resources to growing our prescription and consumer health segments. Coupled with the suspension of clinical development activities and continued execution against our previously planned $15 million cost cutting program, this shift enables the Company to achieve near-term positive Adjusted EBITDA," said Aytu CEO Josh Disbrow in an Oct. 13 press release. The company expects to provide a detailed financial outlook of its strategy at its quarterly investors call scheduled for mid-November.
Seeking Alpha • Sep 27

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Aytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.
Seeking Alpha • Sep 14

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Aytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.
Seeking Alpha • Aug 16

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16
Seeking Alpha • Aug 09

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aytu BioPharma (NASDAQ:AYTU) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,. The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429. Gross proceeds are expected to be ~$10M. Offer is expected to close on Aug.11. Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.
Analyseartikel • May 19

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

It's been a pretty great week for Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders, with its shares surging 18% to...
Analyseartikel • Sep 11

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Josh Disbrow im Vergleich zu den Einnahmen von Aytu BioPharma verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2026n/an/a

-US$34m

Dec 31 2025n/an/a

-US$25m

Sep 30 2025n/an/a

-US$13m

Jun 30 2025US$884kUS$590k

-US$14m

Mar 31 2025n/an/a

-US$1m

Dec 31 2024n/an/a

-US$4m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024US$928kUS$590k

-US$13m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023n/an/a

-US$17m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023US$708kUS$590k

-US$8m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$77m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022US$590kUS$590k

-US$109m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$84m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021US$6mUS$545k

-US$58m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020n/an/a

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020US$2mUS$608k

-US$14m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019US$1mUS$330k

-US$27m

Vergütung im Vergleich zum Markt: JoshDie Gesamtvergütung ($USD883.93K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD642.98K).

Entschädigung vs. Einkommen: JoshDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Josh Disbrow (51 yo)

11.2yrs
Amtszeit
US$883,928
Vergütung

Mr. Joshua R. Disbrow, also known as Josh, serves as Chief Executive Officer at Aytu Biopharma, Inc. since April 16, 2015 and served as its Chairman until 2024. He served as President at Aytu Biopharma, In...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Joshua Disbrow
CEO & Director11.2yrsUS$883.93k1.93%
$ 445.5k
Ryan Selhorn
CFO, Corporate Secretary & Treasurer1.6yrsUS$538.65k0.46%
$ 106.9k
Jarrett Disbrow
Chief Business Officer3.6yrsUS$549.25k0.57%
$ 132.4k
Greg Pyszczymuka
Chief Commercial Officer4.4yrsUS$522.08k0.34%
$ 77.6k
Margaret Cabano
Vice President of Operationsno datakeine Datenkeine Daten
Gerwin Westfield
Senior Vice President of Scientific Affairs1yrkeine Datenkeine Daten
3.6yrs
Durchschnittliche Betriebszugehörigkeit
49yo
Durchschnittliches Alter

Erfahrenes Management: AYTUDas Führungsteam des Unternehmens gilt als erfahren (3.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Joshua Disbrow
CEO & Director10.4yrsUS$883.93k1.93%
$ 445.5k
Vivian Liu
Independent Director3.9yrsUS$87.76k0.18%
$ 42.6k
John Donofrio
Independent Chairman9.9yrsUS$117.76k0.13%
$ 29.6k
Carl Dockery
Independent Director10.2yrsUS$82.76k0.20%
$ 45.5k
Abhinav Jain
Independent Director3yrsUS$77.76k0.18%
$ 41.9k
9.9yrs
Durchschnittliche Betriebszugehörigkeit
59yo
Durchschnittliches Alter

Erfahrener Vorstand: AYTUDie Vorstandsmitglieder gelten als erfahren (9.9 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/06/14 22:45
Aktienkurs zum Tagesende2026/06/12 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/06/30

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Aytu BioPharma, Inc. wird von 5 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Edward WooAscendiant Capital Markets LLC
Jeffrey CohenLadenburg Thalmann & Company
Thomas FlatenLake Street Capital Markets, LLC